Zobrazeno 1 - 10 of 22 pro vyhledávání: '"Martin Šmakal"'
2
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC
Autor: Sergey Orlov, Kaoru Kubota, Jesús Cárdenas Sánchez, Jin-Hyoung Kang, Li Zhang, Alexander N. Fleishman, Joseph K. Park, Vera Hirsh, Konstantinos N. Syrigos, Carlos H. Barrios, Gary Thomas, David H. Henry, Cisio De Oliveira Brandao, Tilman Steinmetz, Dianne Tomita, Pere Gascón, Martin Šmakal, Rajnish Nagarkar, David Gordon
Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(2)
This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling.Adults with stage IV NSCLC expected to r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1e6825173ea32d5a6e5042671f9d1e4
https://pubmed.ncbi.nlm.nih.gov/32127181
Zobrazit plný text záznamu
4
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Autor: Maria Blasinska-Morawiec, Richard Thomas Williams, György Bodoky, Fernando Rivera, Ronald Burkes, Jeffrey Wiezorek, Paul Ruff, Josep Tabernero, Martin Šmakal, Yves Humblet, Mario Edmundo Barugel, Salvatore Siena, Scott D. Patterson, David Cunningham, Mark Rother, Ilona Kocáková, Jacek Jassem, Roger Sidhu, Alan Rong, Jean-Luc Canon, Jean-Yves Douillard, Kelly S. Oliner
Publikováno v: New England Journal of Medicine, Vol. 369, no.11, p. 1023-1034 (2013)
Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca33096bb85a2552a91ba52866c33275
https://doi.org/10.1056/nejmoa1305275
Zobrazit plný text záznamu
6
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer
Autor: Stanislav Spelda, Andrew Coates, Barry L. Dowell, Andrew Krivoshik, Jane Qian, Peter Ansell, Xiangdong Zhou, Gary S. Gordon, Rajendra S. Pradhan, Ann M. Mauer, Martin Šmakal, Evelyn McKeegan, Rosalyn A. Juergens, Charles M. Rudin, Michael S. Wertheim
Publikováno v: Journal of Clinical Oncology. 29:1075-1082
Purpose ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92882bc9bc37b39ddf5c47974e8889d2
https://doi.org/10.1200/jco.2010.32.5944
Zobrazit plný text záznamu
9
Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Autor: Heinz Ludwig, Li Chen, John A. Glaspy, Robert E. Smith, Tudor E. Ciuleanu, Tamás Pintér, Martin Šmakal, Matti S. Aapro, Tom Lillie
Publikováno v: Journal of Clinical Oncology. 26:1040-1050
Purpose The efficacy and safety of darbepoetin alfa (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated. Patients and Methods Patients wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9676654d2b7ae846fa87dab0be006f6c
https://doi.org/10.1200/jco.2007.14.2885
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje